Scientists Dismayed as Texas Leans into Unproved Stem Cell Treatments
By Andrew Joseph,
STAT
| 05. 16. 2017
He made the emotional plea to his colleagues: Pass this bill.
“It might give somebody like my wife a chance to walk,” Texas Representative Drew Springer said through tears late Thursday at the state Capitol in Austin. “I’d trade every one of my bills I’ve passed, every single one of them, to get the chance to hear HB 810.”
HB 810 is one of three bills being considered in the Texas Legislature that would make it easier for sick people to try unproven therapies at their own risk, and cost. Springer’s bill would allow clinics offering unapproved stem cell treatments to treat patients in Texas. HB 661 would permit people with chronic illness to get therapies in early-stage clinical trials — not just terminally ill patients, as the state’s current “right-to-try” law does. And HB 3236 would allow companies to charge patients for unproven therapies.
The debate in Texas echoes a national discussion over how much access patients should have to experimental drugs. For the lawmakers supporting the measures, the issue is about the ability to make one’s own decisions about health...
Related Articles
By Ron Leuty, San Francisco Business Times | 06.16.2025
23andMe's two-step sale to a nonprofit led by former CEO Anne Wojcicki is nothing more than a dance around California's genetic privacy law, state Attorney General Rob Bonta said in a filing late Monday, one day before a judge will...
By Staff, The Associated Press | 06.10.2025
PORTLAND, Ore. — Twenty-seven states and the District of Columbia on Monday filed a lawsuit in bankruptcy court seeking to block the sale of personal genetic data by 23andMe without customer consent. The lawsuit comes as a biotechnology company seeks...
By Donald Earl Collins, Al Jazeera | 05.23.2025
“The picture of the world’s richest man killing the world’s poorest children is not a pretty one,” Microsoft founder and billionaire philanthropist Bill Gates said of Elon Musk during an interview with The Financial Times earlier this month. Gates indirectly...
By Katie Sagaser, The DNA Exchange | 05.27.2025
Disclaimer: The views and opinions expressed in this piece are solely my own and do not represent those of my employer, past or present, or any affiliated institutions. This content is provided for general informational purposes only and does not...